|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,119.00 ILa | -0.89% |
|
-2.57% | -6.24% |
| 06-01 | Kamada Announces FDA Approval of Its New In-House Rabies Virus Neutralization Testing Laboratory | CI |
| 05-13 | Kamada Ltd., Q1 2026 Earnings Call, May 13, 2026 |
Company Valuation: Kamada Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 920.4 | 615 | 1,280 | 1,271 | 1,304 | 1,222 | - | - |
| Change | - | -33.18% | 108.12% | -0.69% | 2.55% | -6.23% | - | - |
| Enterprise Value (EV) | 920.4 | 615 | 1,280 | 1,271 | 1,304 | 1,222 | 1,222 | 1,222 |
| Change | - | -33.18% | 108.12% | -0.69% | 2.55% | -6.23% | 0% | 0% |
| P/E | - | - | - | - | - | - | - | - |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.7x | 1.31x | 2.51x | 2.17x | 2.35x | 2.09x | 1.9x | 1.71x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.09x | 1.9x | 1.71x |
| EV / EBITDA | - | - | 0x | 0x | 0x | 8.13x | 6.73x | 6.46x |
| EV / EBIT | -0x | 0x | 0x | 0x | 0x | 12.2x | 9.77x | 8.07x |
| EV / FCF | -0x | - | -0x | 0x | 0x | 16.2x | 11.6x | 9.17x |
| FCF Yield | -4.52% | - | -0.43% | 10.5% | 3.73% | 6.18% | 8.62% | 10.9% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | - | - | - | - | - | - | - | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 340.3 | 469.1 | 510.9 | 586.9 | 555.7 | 584.7 | 641.9 | 716.6 |
| EBITDA 1 | - | - | 86.36 | 124.5 | 129.3 | 150.3 | 181.7 | 189.2 |
| EBIT 1 | -2.286 | 16.44 | 36.08 | 73.11 | 80.79 | 100 | 125.1 | 151.5 |
| Net income 1 | -7.323 | -8.417 | 29.7 | 52.73 | 62.2 | 72.01 | 103.6 | 127.2 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 20.55 | 13.72 | 22.27 | 22.11 | 22.60 | 21.19 | 21.19 | 21.19 |
| Nbr of stocks (in thousands) | 44,786 | 44,826 | 57,476 | 57,492 | 57,682 | 57,686 | - | - |
| Announcement Date | 3/15/22 A | 3/15/23 A | 3/6/24 A | 3/5/25 A | 3/11/26 A | - | - | - |
1ILS in Million2
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 412M | |
| 15.79x | 3.41x | 9.2x | 0.64% | 62.05B | |
| 26.92x | 5.45x | 15.93x | 0.59% | 54.52B | |
| 33.97x | 11.5x | 21.69x | -.--% | 41.55B | |
| -52.51x | 3.11x | 9.2x | 3.5% | 39.06B | |
| 31.74x | 3.42x | 10.51x | -.--% | 29.02B | |
| -7.4x | 10.45x | -6.37x | -.--% | 25.38B | |
| 14.83x | 2.6x | 8.05x | -.--% | 19.62B | |
| 47.78x | 5.2x | 36.07x | -.--% | 16.89B | |
| 24.64x | 5.1x | 13.75x | -.--% | 15.89B | |
| Average | 15.08x | 5.58x | 13.11x | 0.53% | 30.44B | |
| Weighted average by Cap. | 13.26x | 5.57x | 12.60x | 0.69% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- KMDA Stock
- Valuation Kamada Ltd.
Select your edition
All financial news and data tailored to specific country editions
